Li Yuman, Wen Jiahao, Liang Dingyue, Sun Haitao
Clinical Biobank Center, Microbiome Medicine Center, Department of Laboratory Medicine, Zhujiang Hospital and the Second Clinical Medical College, Southern Medical University, Guangzhou, China.
Neurosurgery Center, The National Key Clinical Specialty, The Engineering Technology Research Center of Education Ministry of China on Diagnosis and Treatment of Cerebrovascular Disease, Guangdong Provincial Key Laboratory on Brain Function Repair and Regeneration, The Neurosurgery Institute of Guangdong Province, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Front Mol Biosci. 2022 Jun 20;9:785314. doi: 10.3389/fmolb.2022.785314. eCollection 2022.
Intracranial aneurysms (IA) are abnormal expansions of the intracranial arteries. Once it ruptures, the mortality and disability rate are high. The cost of imaging examinations is high, and rupture risk cannot be predicted, making it difficult for high-risk groups to be screened and prevented. Thus, clinically effective biomarkers are required to screen high-risk groups, estimate the risk of rupture, and determine the appropriate early intervention step. This article introduces the current research and application of exosome-derived microRNA (miRNA) as biomarkers of intracranial aneurysms and their limitations, which can give researchers a general overview of the research in this field. It can also serve as a reference point for selecting related research directions.
颅内动脉瘤（IA）是颅内动脉的异常扩张。一旦破裂，死亡率和致残率都很高。影像学检查成本高，且无法预测破裂风险，使得高危人群难以进行筛查和预防。因此，临床上需要有效的生物标志物来筛查高危人群、评估破裂风险并确定合适的早期干预措施。本文介绍了外泌体衍生的微小RNA（miRNA）作为颅内动脉瘤生物标志物的当前研究与应用及其局限性，可为该领域的研究人员提供总体概况，也可为选择相关研究方向提供参考。
